- Home
- SSY vs GRI Comparison
SSY vs GRI Comparison
Compare SSY & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSY
- GRI
- Stock Information
- Founded
- SSY 1959
- GRI 2018
- Country
- SSY United States
- GRI United States
- Employees
- SSY N/A
- GRI N/A
- Industry
- SSY Hospital/Nursing Management
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- SSY Health Care
- GRI Health Care
- Exchange
- SSY Nasdaq
- GRI Nasdaq
- Market Cap
- SSY 5.5M
- GRI 6.1M
- IPO Year
- SSY N/A
- GRI N/A
- Fundamental
- Price
- SSY $0.85
- GRI $0.72
- Analyst Decision
- SSY
- GRI Strong Buy
- Analyst Count
- SSY 0
- GRI 2
- Target Price
- SSY N/A
- GRI $11.50
- AVG Volume (30 Days)
- SSY 991.4K
- GRI 182.9K
- Earning Date
- SSY 02-11-2025
- GRI 11-14-2024
- Dividend Yield
- SSY N/A
- GRI N/A
- EPS Growth
- SSY N/A
- GRI N/A
- EPS
- SSY N/A
- GRI N/A
- Revenue
- SSY $31,808,000.00
- GRI N/A
- Revenue This Year
- SSY N/A
- GRI N/A
- Revenue Next Year
- SSY N/A
- GRI N/A
- P/E Ratio
- SSY N/A
- GRI N/A
- Revenue Growth
- SSY N/A
- GRI N/A
- 52 Week Low
- SSY $0.53
- GRI $0.30
- 52 Week High
- SSY $1.91
- GRI $65.00
- Technical
- Relative Strength Index (RSI)
- SSY 46.48
- GRI 44.58
- Support Level
- SSY $0.89
- GRI $0.68
- Resistance Level
- SSY $0.92
- GRI $0.77
- Average True Range (ATR)
- SSY 0.15
- GRI 0.07
- MACD
- SSY -0.02
- GRI -0.01
- Stochastic Oscillator
- SSY 6.76
- GRI 16.44
About SSY SunLink Health Systems Inc.
SunLink Health Systems Inc is engaged in providing retail pharmacy services. The company operates its business through segments namely the Healthcare Services segment and Pharmacy segment. The Healthcare Services segment includes subsidiaries that own and operate licensed-bed, acute care hospitals, which includes bed geriatric psychology unit, and nursing home; own medical buildings, which are leased to unaffiliated healthcare providers, and adjacent vacant land; and provides information technology to outside customers. The Pharmacy segment, which is the key revenue generator is composed of retail pharmacy products and services that are conducted in rural markets; institutional pharmacy services; pharmacy services; and durable medical equipment.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.